444 related articles for article (PubMed ID: 24689054)
1. Aberrant glycosylation as biomarker for cancer: focus on CD43.
Tuccillo FM; de Laurentiis A; Palmieri C; Fiume G; Bonelli P; Borrelli A; Tassone P; Scala I; Buonaguro FM; Quinto I; Scala G
Biomed Res Int; 2014; 2014():742831. PubMed ID: 24689054
[TBL] [Abstract][Full Text] [Related]
2. Glycans as cancer biomarkers.
Adamczyk B; Tharmalingam T; Rudd PM
Biochim Biophys Acta; 2012 Sep; 1820(9):1347-53. PubMed ID: 22178561
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein.
de Laurentiis A; Gaspari M; Palmieri C; Falcone C; Iaccino E; Fiume G; Massa O; Masullo M; Tuccillo FM; Roveda L; Prati U; Fierro O; Cozzolino I; Troncone G; Tassone P; Scala G; Quinto I
Mol Cell Proteomics; 2011 May; 10(5):M111.007898. PubMed ID: 21372249
[TBL] [Abstract][Full Text] [Related]
4. Overview of Characterizing Cancer Glycans with Lectin-Based Analytical Methods.
Pearson AJ; Gallagher ES
Methods Mol Biol; 2019; 1928():389-408. PubMed ID: 30725466
[TBL] [Abstract][Full Text] [Related]
5. Aberrant glycosylation associated with enzymes as cancer biomarkers.
Meany DL; Chan DW
Clin Proteomics; 2011 Jun; 8(1):7. PubMed ID: 21906357
[TBL] [Abstract][Full Text] [Related]
6. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.
Ho WL; Hsu WM; Huang MC; Kadomatsu K; Nakagawara A
J Hematol Oncol; 2016 Sep; 9(1):100. PubMed ID: 27686492
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation Changes in Brain Cancer.
Veillon L; Fakih C; Abou-El-Hassan H; Kobeissy F; Mechref Y
ACS Chem Neurosci; 2018 Jan; 9(1):51-72. PubMed ID: 28982002
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques.
Haga Y; Ueda K
Glycoconj J; 2022 Apr; 39(2):303-313. PubMed ID: 35156159
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of mucin-type O-glycosylation (MTOG) induced by peracetyl N-thioglycolyl-d-galactosamine (Ac
Dwivedi V; Saini P; Tasneem A; Agarwal K; Sampathkumar SG
Biochem Biophys Res Commun; 2018 Nov; 506(1):60-65. PubMed ID: 30336974
[TBL] [Abstract][Full Text] [Related]
10. Glycan-specific antibodies as potential cancer biomarkers: a focus on microarray applications.
Tikhonov A; Smoldovskaya O; Feyzkhanova G; Kushlinskii N; Rubina A
Clin Chem Lab Med; 2020 Sep; 58(10):1611-1622. PubMed ID: 32324152
[TBL] [Abstract][Full Text] [Related]
11. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death.
Hernandez JD; Nguyen JT; He J; Wang W; Ardman B; Green JM; Fukuda M; Baum LG
J Immunol; 2006 Oct; 177(8):5328-36. PubMed ID: 17015718
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation: a hallmark of cancer?
Vajaria BN; Patel PS
Glycoconj J; 2017 Apr; 34(2):147-156. PubMed ID: 27975160
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated CD43 glycoforms as target of immunotherapy.
Tuccillo FM; Palmieri C; Fiume G; de Laurentiis A; Schiavone M; Falcone C; Iaccino E; Galandrini R; Capuano C; Santoni A; D'Armiento FP; Arra C; Barbieri A; Dal Piaz F; Venzon D; Bonelli P; Buonaguro FM; Scala I; Mallardo M; Quinto I; Scala G
Mol Cancer Ther; 2014 Mar; 13(3):752-62. PubMed ID: 24356816
[TBL] [Abstract][Full Text] [Related]
14. Cancer glycan epitopes: biosynthesis, structure and function.
Pearce OMT
Glycobiology; 2018 Sep; 28(9):670-696. PubMed ID: 29546349
[TBL] [Abstract][Full Text] [Related]
15. Relevance of glyco-biomakers and glycan profiles in cancer stem cells.
Pujari R; Dubey SK
Glycobiology; 2024 Apr; 34(6):. PubMed ID: 36864577
[TBL] [Abstract][Full Text] [Related]
16. Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.
Chugh S; Gnanapragassam VS; Jain M; Rachagani S; Ponnusamy MP; Batra SK
Biochim Biophys Acta; 2015 Dec; 1856(2):211-25. PubMed ID: 26318196
[TBL] [Abstract][Full Text] [Related]
17. Glycoproteins in the Sera of Oncological Patients.
Hernychová L; Uhrík L; Nenutil R; Novotný MV
Klin Onkol; 2019; 32(Supplementum 3):39-45. PubMed ID: 31627705
[TBL] [Abstract][Full Text] [Related]
18. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.
Thomas D; Rathinavel AK; Radhakrishnan P
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188464. PubMed ID: 33157161
[TBL] [Abstract][Full Text] [Related]
19. Lectin biosensors in cancer glycan biomarker detection.
Silva MLS
Adv Clin Chem; 2019; 93():1-61. PubMed ID: 31655728
[TBL] [Abstract][Full Text] [Related]
20. A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer.
Cornelissen LA; Van Vliet SJ
Biomolecules; 2016 May; 6(2):. PubMed ID: 27153100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
